Table 1.
Performance of current nomogram and 7th AJCC staging systems in patients with liposarcoma.
|
Training (n = 4013) |
Test (n = 1720) |
|||||
|---|---|---|---|---|---|---|
| Statistical index | Z | P | Statistical index | Z | P | |
| C-index (95%CI) | ||||||
| Nomogram | 79.40% (79.36%–79.44%) | 46.39 | * | 80.20% (80.11%–80.29%) | 31.84 | * |
| AJCC | 68.20% (68.15%–68.25%) | 23.49 | * | 71.30% (71.19%–71.41%) | 18.27 | * |
| IDI (%) | ||||||
| 3-year | 9.76% (9.12%–10.40%) | 17.59 | * | 8.26% (7.27%–9.25%) | 9.41 | * |
| 5-year | 12.05% (11.30%–12.80%) | 18.87 | * | 10.05% (8.88%–11.21%) | 9.89 | * |
| NRI (95%CI) | ||||||
| 3-year | 0.5392 (0.4754–0.6365) | 0.4966 (0.3399–0.6488) | ||||
| 5-year | 0.6470 (0.5907–0.7299) | 0.5244 (0.3567–0.6879) | ||||
*P < 0.00001AJCC.
American Joint Committee on Cancer; C-index, Harrell’s C-index; IDI, integrated discrimination improvement; NRI, net reclassification improvement; CI, confidence interval.